Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes pill may reverse early heart damage, small study suggests

NCT ID NCT07186153

Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at whether common diabetes drugs called SGLT2 inhibitors (like empagliflozin and dapagliflozin) can improve the structure and function of the heart's left atrium in people with type 2 diabetes. Researchers will use advanced ultrasound to measure heart changes in 100 adults aged 40-75 before and after 6 months of treatment. The goal is to see if these drugs can reverse early signs of heart strain caused by diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SGLT2 inhibitors (empagliflozin, dapagliflozin)
What this could lead to
If successful, this could show that SGLT2 drugs help reverse early heart damage in people with diabetes, potentially reducing future heart failure risk.
What could go wrong
This is a small, early-phase study with only 100 participants and no control group. Results may not apply to all diabetes patients, and the heart changes measured may not translate to fewer heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 40-75 years with a diagnosis of T2DM on stable antidiabetic therapy not including SGLT2 inhibitors

Ages

40 to 75 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed T2DM on antidiabetic medication not including SGLT2 inhibitors. * HbA1c ≤ 7%. * Age 40-75 years. * Sinus rhythm. * Informed consent obtained Exclusion Criteria: * History of atrial fibrillation or flutter. * Patients treated with SGLT2 inhibitors. * Severe mitral valve regurgitation or stenosis. * Previous myocardial infarction. * Previous percutaneous coronary intervention(PCI) or coronary artery bypass grafting (CABG). * LV Ejection fraction \<50% . * Severe renal impairment (eGFR \< 30 mL/min/1.73 m²) * Uncontrolled hypertension (BP \> 160/100 mmHg) * Inadequate echocardiographic windows or incomplete data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SGLT 2 inhibitors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SGLT 2 inhibitors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.